SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ausdauer who wrote (1456)	2/7/2003 2:55:07 PM
From: Biomaven	Read Replies (1) of 1477

The bulk of what JNJ is paying for is Natrecor. If all they wanted was the P38 program, they could easily partner instead - cost them $50m upfront instead of $2 billion. Natrecor estimated peak US sales are of the order of $500m, even without assuming good results from their outpatient trial. If that trial goes well, then it could be a $750m+ drug. Add European sales, and you will see why I am not overjoyed at losing my SCIO stock. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next